10-K: Lineage Cell Therapeutics Reports 2024 Results, Highlights OpRegen and OPC1 Progress

Lineage Cell Therapeutics details its 2024 financial results and provides updates on its key programs, including OpRegen for geographic atrophy and OPC1 for spinal cord injuries.

Summary

• Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological and ophthalmic conditions.
• The company's lead program, OpRegen (RG6501), is being developed in collaboration with Roche and Genentech for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
• Lineage received a $50.0 million upfront payment from Roche in January 2022 and is eligible for up to $620.0 million in additional milestone payments, plus tiered double-digit royalties on net sales.
• In May 2024, Lineage entered into a Services Agreement with Genentech to provide supplemental support for the OpRegen program.
• Roche and Genentech received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for OpRegen in September 2024.
• Lineage's internally owned product candidate, OPC1, is an allogeneic oligodendrocyte progenitor cell therapy for spinal cord injury (SCI).
• The company filed an IND amendment for OPC1 in December 2023 and received FDA authorization to proceed with the DOSED clinical study in January 2025.
• The DOSED study is expected to commence enrollment in the second quarter of 2025.
• Lineage closed two financings totaling $44 million in gross proceeds and could receive an additional $36 million upon full exercise of OpRegen clinical milestone-linked warrants.
• The company's operating losses for 2024 were $21.5 million, with an accumulated deficit of $403.5 million as of December 31, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments in the company's pipeline and collaborations, the ongoing operating losses and need for additional funding create uncertainty.

Positives

• Collaboration with Roche and Genentech for OpRegen provides significant funding and expertise.
• RMAT designation for OpRegen offers an expedited regulatory path.
• Initiation of the DOSED clinical study for OPC1 represents progress in the company's internal pipeline.
• Successful financings provide capital to support ongoing operations.
• OpRegen has demonstrated the potential to slow, stop or reverse disease progression in GA secondary to AMD in a Phase 1/2a clinical trial.

Negatives

• The company has incurred operating losses since inception and had an accumulated deficit of $403.5 million as of December 31, 2024.
• The company is dependent on its collaboration with Roche to develop and commercialize OpRegen.
• The company will need to raise substantial additional capital to complete the development and seek regulatory approval of its product candidates.
• The FDA review of the IND amendment and the DOSED study protocol was ongoing throughout 2024.

Risks

• Reliance on Roche for OpRegen development and commercialization poses a risk if the collaboration is unsuccessful or terminated.
• Clinical development of cell therapies is a lengthy and expensive process with uncertain outcomes.
• The company's manufacturing operations are concentrated in Jerusalem, Israel, which exposes it to political and economic risks.
• The company may not be able to obtain additional funding from CIRM to support OPC1 development.
• The company faces significant competition in the cell therapy industry.
• The company may be subject to product liability claims.
• The company currently has no marketing and sales force or distribution capabilities.
• The company's intellectual property may be insufficient to protect its products.
• The company relies on third parties for various aspects of its operations, which could lead to delays or increased costs.
• The market price of the company's common shares has been and may continue to be volatile.
• Insiders continue to have substantial influence over the company.
• There is no assurance that the company will be able to maintain compliance with the NYSE Americans continued listing standards.

Future Outlook

Lineage expects its cash, cash equivalents, and marketable securities as of December 31, 2024, will be sufficient to fund its planned operations for at least twelve months from the issuance date of the consolidated financial statements included elsewhere in this report.

Industry Context

The announcement highlights Lineage's position in the competitive cell therapy industry, particularly in the areas of ophthalmology and neurology. The collaboration with Roche and Genentech underscores the growing interest and investment in cell-based therapies for diseases with unmet medical needs.

Comparison to Industry Standards

• Lineage is competing with companies like AbbVie, Novo Nordisk A/S, Bayer AG, Regeneron Pharmaceuticals, Santen Pharmaceuticals, Sana Biotechnology Inc., jCyte, Inc., Astellas Pharma Inc., and Apellis Pharmaceuticals Inc. in the cell therapy space.
• The company's approach of using allogeneic cell therapies distinguishes it from some competitors that are focused on gene therapies or other treatment modalities.
• The RMAT designation for OpRegen is a positive sign, as it indicates the FDA's recognition of the potential of regenerative medicine therapies to address unmet medical needs.

Related Party Transactions

• Broadwood Partners purchased 6,730,770 common shares in the February 2024 registered direct offering.
• Don Bailey, a member of Lineage's board of directors, purchased 96,155 shares in the February 2024 registered direct offering.
• Broadwood Partners purchased 7,894,737 common shares and an accompanying warrant in the November 2024 registered direct offering.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful development and commercialization of cell therapies, but also risk of dilution and volatility.
• Employees: Opportunity to contribute to innovative therapies, but also risk of job insecurity due to financial challenges.
• Patients: Potential for new treatment options for serious neurological and ophthalmic conditions.
• Collaborators: Opportunity to partner with a company developing novel cell therapies.

Next Steps

• Commence enrollment in the DOSED clinical study in the second quarter of 2025.
• Apply for additional funding from CIRM to support continued clinical development of OPC1.
• Continue execution under the collaboration with Roche and Genentech for OpRegen.
• Evaluate preclinical and research product candidates, ANP1 and PNC1, for advancement into human testing.

Key Dates

Keywords

OpRegen, OPC1, cell therapy, Roche, Genentech, spinal cord injury, geographic atrophy, AMD, clinical trial, RMAT designation, allogeneic, biotechnology